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ABSTRACT
Aims: To evaluate the effectiveness and safety of Posterior Sub-Tenon (PST) Triamcinolone 
Acetonide (TA) injection for persistent macular oedema associated with non-ischemic Central 
Retinal Vein Occlusion (CRVO) or Branch Retinal Vein Occlusion (BRVO) in non-vitrecto-
mized eye. 
Methods: Fourteen consecutive eyes of 14 patients characterized by macular oedema lasting 
more than 3 months and with a visual acuity of less than 20/40 were enrolled. Six eyes pre-
sented with BRVO, 8 eyes with CRVO. PST injection of 40 mg TA was performed in topical 
anaesthesia. All patients were phakic, and followed for at least 6 months. Snellen visual acuity 
converted to LogMAR units and anatomic responses were evaluated before, and at 1, 3, 6, and 
12 (if required) months after injections and re-injection considered.
Results: In the BRVO group, mean foveal thickness was 548.2±49.50 µm preoperatively, 
and 452.8±56.2 µm and 280.8±62.5 µm at 1 and 12 month follow-up, respectively. Statistical 
analysis showed significant differences between preoperative and postoperative measurements 
(P<.05, paired t test) 3 months after injections. Improvement of visual acuity by at least 0.2 
LogMAR was seen in 3(50%) of the 6 eyes. No re-injection was needed. In the CRVO group, 
mean foveal thickness was 543.7±34.4 µm preoperatively, and 283.0±29.0 µm and 234.8±23.6 
µm at 1 and 12 month follow-up, respectively. Statistical analysis showed significant differenc-
es between preoperative and postoperative measurements (P<.05, paired t test). Improvement 
of visual acuity by at least 0.2 LogMAR was seen in 7 eyes (88%). Mean number of re-injection 
was of 2.1±0.3. Intraocular pressure elevation of 22 mm Hg or higher was found in 2/14 eyes 
(14%). Cataract progression was noted in 5/14 eyes (36%).
Conclusions: PST injection of TA appears to be as safe and effective treatment for chronic 
macular oedema associated due to both non-ischemic BRVO or CRVO, with a better efficacy 
in BRVO.
KEYWORDS: Branch/Central retinal vein occlusion; Chronic macular oedema; Triamcinolone; 
Posterior sub-Tenon injection. 
ABBREVIATIONS: PST: Posterior sub-Tenon; TA: Triamcinolone Acetonide; CRVO: Central 
Retinal Vein Occlusion; BRVO: Branch Retinal Vein Occlusion; Anti-VEGF: Anti-Vascular 
Endothelial Growth Factor; IOP: Intraocular pressure; SEM: Standard Error of the Mean; ILM: 
Internal Limiting Membrane; LOCS II: Lens Opacities Classification System, version II. 
INTRODUCTION
 Macular oedema is the most common cause of visual loss among patients with Reti-
nal Vein Occlusion (RVO).1,2 The only proven treatment before the Anti-Vascular Endothelial 
Growth Factor (Anti-VEGF) intravitreal injection era consisted of grid pattern laser photoco-
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agulation which is based on the results of Branch Vein Occlusion 
Study (BVOS).2 In the BVOS, patients received laser treatment 
when vision had been lower than 20/40 for at least 3 months and 
if there was no macular ischemia. The rationale for this waiting 
period was that one third of patients with retinal vein occlusion 
may have spontaneous resolution of macular oedema within this 
time span.1-3 Grid laser treatment has also been advocated for 
macular edema in Central Retinal Vein Occlusion (CRVO). This 
therapy only had a positive effect on the edema, however not on 
visual acuity.1
 Anti-VEGF intravitreal injection is nowadays widely 
considered as the first choice for retinal vein occlusion macular 
edema management with effective subsequent visual acuity im-
provement.4,5 However the need of frequent administration, the 
risk of potential local and systemic complication and their high 
cost, unravelled the search of alternative treatment.6 
 Triamcinolone Acetonide (TA) is a corticosteroid that 
has been reported to be efficacious in the treatment of retinal 
vein occlusion induced macular edema when administrated in-
travitreally.7,8 Nevertheless, intravitreal procedures may be as-
sociated with endophthalmitis, vitreous haemorrhage, retinal 
detachment, and high intraocular pressure. In some studies less 
invasive procedures such as Posterior sub-Tenon (PST) TA infu-
sion9 or TA injection in vitrectomized eyes10 have been evaluated 
as a treatment for macular oedema associated with retinal vein 
occlusion.
 In the present study we have evaluated the efficacy and 
safety of PST injection of TA in primarily non-vitrectomised 
eyes with severe macular oedema secondary to non-ischemic 
branch retinal vein occlusion (BRVO) or central retinal vein oc-
clusion (CRVO).
MATERIALS AND METHODS
 The study adhered to the tenets of Helsinki. We includ-
ed 14 consecutive eyes of 14 patients, who had severe macular 
oedema secondary to non-ischemic branch retinal vein occlu-
sion (BRVO) or central retinal vein occlusion (CRVO) lasting 
more than 3 months after onset, with a visual acuity of less than 
20/40 and without prior treatment. The patients were evaluated 
on the basis of central retinal thickness using a horizontal 5 mm 
Optical Coherence Tomography (OCT) scan through the macula 
(Stratus system, OCT Model 3000, software version 3.0; Carl 
Zeiss-Meditec, Dublin, CA, USA), Best Corrected Visual Acu-
ity (BCVA), Intraocular pressure (IOP) and cataract progression 
as Lens Opacities Classification System, version II (LOCS II) 
classification system.11 BCVA was obtained using Snellen charts 
and converted to LogMAR units. PST injection of TA injection 
(Kenacort A40, Dermapharm AG, Hünenberg, Switzerland) was 
performed in an outpatient setting. None of our patients had 
previous vitrectomy. After topical oxybuprocaine hydrochloride 
4% had been instilled, a cotton tip soaked in 4% tetracaine was 
placed over the superotemporal quadrant for 1 minute as the pa-
tient was asked to look inferonasally. The upper eyelid was el-
evated manually and a 25 G needle was then passed through the 
conjunctiva and Tenon’s capsule into the PST space, and 40 mg 
of TA was injected. Ofloxacin 3 mg/ml was instilled three times 
daily for 1 week. BCVA, central retinal thickness and IOP were 
assessed at 1, 3, 6, and 12 months after the injection or prior to 
these dates if the patient re-attended the clinic due to visual loss. 
Criteria for re-injections included worsening of macular oedema 
thickness on OCT defined as an increase of 100 microns or more 
coupled with worsening of the BCVA defined as a decrease of 2 
or more lines after initial improvement following the first injec-
tion. These patients were then seen again after the second injec-
tion at the intervals described above to ascertain improvement 
both clinically and on OCT. 
 Third injections were performed if both BCVA and 
OCT worsened again during follow-up after the second injec-
tion. If patients showed no improvement after the first injection 
they continued to receive the standard treatment including anti-
VEGF intravitreal injection and/or macular grid laser for BRVO 
patients versus clinical follow-up for CRVO patients.
 Changes overtime in LogMAR visual acuity, central 
retinal thickness and IOP were compared using the paired t test. 
The differences between BRVO and CRVO groups in LogMAR 
visual acuity, central retinal thickness, IOP and other continuous 
variables were compared using the Mann-Whitney U test. Linear 
correlation between the number of required PST injections and 
cataract progression or IOP elevation, as well as with macular 
thickness and BCVA, was tested with the Pearson correlation 
co-efficient. Data were expressed with Standard Error of the 
Mean (SEM).
RESULTS
 The patient characteristics of both groups are shown in 
Tables 1 and 2. Six patients were included in the BRVO group. 
The mean patient age was 64.3±4.2 years (range: 52 to 80 years) 
and the mean duration of the symptoms, according to patient 
history before TA injection, was 13.7±5.0 months (range: 3 to 24 
months). Eight patients were part in the CRVO group. Mean age 
was 70.3±2.9 years (range: 59 to 81 years) and the mean duration 
of the disease was 7.6±2.6 months (range: 3 to 24 months). No 
statistically significant differences were found between groups 
regarding age (P=0.15, Mann-Whitney test), or duration of the 
occlusion (P=0.09, Mann-Whitney test).
 
BRVO Group
 Data are summarized in Table 3. Patient 5 stopped at-
tending our clinic 6 months after injection for personal reason. 
The mean follow-up period after injection was 9.0±3.3 months 
(range: 6 to 12 months). Mean foveal thickness was 548.2±49.0 
µm preoperatively, 452.8±56.2 µm at 1 month follow-up, 
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Patient Age(years)
Duration 
(months)
Pre-VA
(LogMAR)
Final VA
(LogMAR)
Pre-OCT
thickness
(µm)
Final-OCT
thickness
(µm)
Follow-up 
(months)
Recurrence and 
date of re-injection
1 60 7 0.8 0.7 660 400 12 -
2 60 6 1.0 0.7 672 340 6 -
3 74 24 0.4 0.1 439 250 12 -
4 52 3 1.3 0.1 630 190 12 -
5 60 24 0.5 0.5 400 232 6 -
6 80 18 0.6 0.5 488 583 6 -
Patient Age(years)
Duration 
(months)
Pre-VA
(LogMAR)
Final VA
(LogMAR)
Pre-OCT
thickness
(µm)
Final-OCT
thickness
(µm)
Follow-up 
(months)
Recurrence and date 
of re-injection
1 64 3 0.8 0.2 630 150 12 2 and 4 months
3 81 7 0.4 0.1 550 175 12 -
4 72 24 0.4 0.1 431 275 12 6 months
5 59 3 0.7 0.1 670 340 12 -
6 81 3 1.0 0.5 500 265 12 3 and 6 months 
6 63 9 0.6 0.4 691 224 12 6 months
7 68 4 0.9 0.2 484 200 12 6 and 11 months
8 74 3 0.4 0.5 480 300 12 1 and 3 months
Table 1: Baseline and follow-up data for BRVO patients treated with posterior sub-tenon triamcinolone injection. Duration from onset of visual impairment to 
injection. VA: Visual acuity.
Table 2. Baseline and follow-up data for CRVO patients treated with posterior sub-tenon triamcinolone injection. Duration from onset of visual impairment to 
injection. VA: Visual acuity.
Time point
Foveal Thickness (µm) Visual Acuity (LogMAR) Pearson correlation IOP (mm Hg)
Mean±SEM P value Mean±SEM P value R2 P Value Mean±SEM P value
Baseline (n = 6) 548.2±49.0 NA 0.77±0.14 NA  0.66 0.05  16.2±1.3 NA
1 month (n = 6) 452.8±56.2 0.07 0.48±0.11 0.07  0.40 0.18  15.8±0.7 0.82
3 month (n =6) 340.0±5.8 0.01 0.42±0.13 0.05  0.25 0.67  20.0±5.1 0.44
6 month (n=3) 390.3±105.3 0.01 0.33±0.18 0.05  0.89 0.21  18.0±1.1 0.63
12 month (n = 3) 280.8±62.5 0.01 0.30±0.20 0.04  0.92 0.18  18.0±2.0 0.50
Table 3: Summary of changes in foveal thickness, visual acuity and intraocular pressure (IOP) for BRVO. Differences were analyzed with the paired t test and 
considered significant when P<0.05. Foveal thickness and visual acuity was correlated by the Pearson R2 correlation test and considered significant when 
P<0.05.
340.0±5.8 µm at 3 month follow-up, 390.3±105.3 µm at 6 month 
and 280.8±62.5 µm at 12 month follow-up. Statistical analysis 
showed significant and sustained decreased in foveal thickness 
between preoperative and postoperative measurements from 
the third months after PST injection (P>.05, at 1, 3, 6 and 12 
months, paired t test) without need of further injection. Visu-
al acuity improved also significantly 3 months after injections 
from preoperative 0.77±0.14 LogMAR (range: 1.3 to 0.4) to 
0.30±0.20 LogMAR (range: 0.7 to 0.1; P=0.04, paired t test) at 
12 month follow-up. Improvement of visual acuity by at least 
0.2 LogMAR was seen in 3(50.0 %) of the 6 eyes. Time of injec-
tion (duration of the disease) did not influence final visual acuity 
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(Pearson correlation co-efficient, r2=0.01, p=0.84).
CRVO Group
 Data are summarized in Table 4. The mean follow-up 
period after injection was of 12 months. Average re-injection 
number was 2.1±0.3. Mean foveal thickness was 543.7±34.4 
µm preoperatively, 283.0±29.0 µm at 1 month follow-up, 
372.0±60.1 µm at 3 month follow-up, 255.±22.4 µm at 6 month 
and 234.8±23.6 µm at 12 month follow-up. Statistical analysis 
showed significant differences between preoperative and post-
operative foveal thickness measurements (P<.01, at 1, 3, 6 and 
12 months, paired t test). Visual acuity improved significantly 
from preoperative 0.65±0.08 LogMAR (range: 1.0 to 0.4) to 
0.26±0.06 LogMAR (range: 0.5 to 0.1; P<0.01, paired t test) 
after 12 months of follow-up with a non-significant value at 3 
months which correspond to the mean interval 4.0±2.0 months 
before a second re-injection was needed. Improvement of visual 
acuity by at least 0.2 LogMAR was seen in 7(87.5 %) of the 8 
eyes. 
 Duration of the disease did not influence final visual 
acuity (Pearson correlation co-efficient, r2=0.14, p=0.18). 
 No statistically significant differences were found 
between BRVO and CRVO groups regarding foveal thick-
ness before and after treatment (P=1.0, P=0.13, respectively, 
Mann-Whitney test), or visual acuity before and after treatment 
(P=0.55, P=0.16, respectively, Mann-Whitney test). In 6(0.75%) 
eyes of the CRVO group, additional injections were performed 
because of recurrent macular edema, and 4(50%) of those eyes 
required a third injection. Intraocular pressure elevation of 22 
mm Hg or higher was found in 2/14 eyes (14%, CRVO group) 
but were not associated with the number of injections (Pearson 
correlation co-efficient, r2<0.01, p>0.97). The IOP in those eyes 
could be controlled with topical low-pressure medication. All 
eyes were phakic and cataract progression was noted in 5 eyes (1 
eye BRVO and 4 eyes CRVO), of which patient 3 of the CRVO 
group had cataract extraction 6 months after the injection. Cata-
ract progression was not correlated with the number of injec-
tions (Pearson correlation co-efficient, r2=0.04, p=0.48).
DISCUSSION
 Several studies have suggested various invasive op-
tions to treat CRVO and BRVO including intravitreal tissue plas-
minogen activator,12,13 radial optic neurotomy,14 sheathotomy,15 
macular decompression using vitrectomy and Internal Limit-
ing Membrane (ILM) peeling,16 and laser induced chorioretinal 
anastomosis.17 Intravitreal TA has been shown to be effective in 
treating macular oedema due to CRVO and BRVO.8,9,18 However, 
intravitreal injections carry considerable risks, including acute 
infectious endophthalmitis19 and pseudopendophthalmitis.20
 PST injection seems to be less effective than intravit-
real TA or grid laser photocoagulation for treatment of macu-
lar edema in BRVO.21 However, PST of TA on the other hand 
may give rise to intravitreal TA concentrations comparable to 
the level achieved by intravitreal injection22 without incurring 
the same risks. TA delivered via the posterior sub-tenon route 
has previously been widely used for treating macular edema due 
to Irvine-Gass Syndrome,23 diabetes,24 and uveitis.25 Lin, et al. 
reported the clinical outcome of PST of TA in the early treatment 
of macular edema in CRVO lasting for not more than 15 days 
prior to the injection.26 It was concluded that early injections are 
effective in reversing macular edema and improving visual acu-
ity. However, since one third of patients with retinal vein occlu-
sion may have spontaneous resolution of macular edema within 
the first 3 to 4 months,1-3 we performed the sub-tenon injection of 
TA only after 3 months in the present study. 
 Our results showed that this form of treatment is effec-
tive in reversing macular oedema and improving visual acuity in 
retinal vein occlusion even after the presence of macular edema 
for several months. Those finding are in keeping with some re-
cent reports.27,28 However our study is the first one to compare 
PST injection between BRVO and CRVO patient. This treat-
ment might be more effective in BRVO than CRVO patient, as 
only one injection was required in BRVO patients. In the CRVO 
group, while OCT and visual acuity values improved during the 
first months, patients often necessitated a second or a third injec-
tion after the transient effect of a PST. Compared to the CVOS 
data, where only 20% of the eyes with an initial VA ranging from 
Time point
Foveal Thickness(µm) Visual Acuity (LogMAR) Pearson correlation IOP
Mean±SEM P value Mean±SEM P value R2 P value Mean±SEM P value
Baseline (n = 8) 543.7±34.4 NA 0.65±0.08 NA  0.02 0.36 15.8±0.7 NA
1 month (n = 8) 283.0±29.0<.01 0.38±0.03<.01  0.23 0.11 18.9±1.5 0.11
3 month (n = 8) 372.±60.1<.01 0.43±0.15 0.11  0.34 0.06 17.6±1.5 0.40
6 month (n = 8) 255.0±22.4<.01 0.34±0.07<.01  0.27 0.12 15.3±1.0 0.69
12 month (n = 8) 234.8±23.6<.01 0.26±0.06<.01  0.25 0.16 17.9±1.3 0.27
Table 4: Summary of changes in foveal thickness, visual acuity and intraocular pressure (IOP) for CRVO. Difference were analyzed by the paired t test and considered 
significant when P<0.05. 
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0.4 to 1.0 LogMAR improve to 0.4 or better, our results showed 
that 75% of the eyes (6/8) improved to that level. 
 Although the IOP rise in our study (2 eyes, 14%) is 
better compared to the IOP after intravitreal injections (20-
33%),3,7,18,24 it could be still argued that the incidence of intra-
ocular pressure elevation is very high, and that TA injections 
should thus only be used in exceptional circumstances. How-
ever, in view of the devastating long-term effects of retinal vein 
occlusions on visual acuity we believe that these side effects can 
be managed either medically or surgically, and that this form of 
treatment should be evaluated further given the ease of injec-
tion, the low costs as well as the low risks of its application in an 
outpatient setting.
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